fenfluramine has been researched along with Parkinson Disease in 6 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McFarland, K | 1 |
| Price, DL | 1 |
| Bonhaus, DW | 1 |
| Kostić, VS | 1 |
| Lecić, D | 1 |
| Doder, M | 1 |
| Marinković, J | 1 |
| Filipović, S | 1 |
| Volpi, R | 1 |
| Caffarra, P | 1 |
| Boni, S | 1 |
| Scaglioni, A | 1 |
| Malvezzi, L | 1 |
| Saginario, A | 1 |
| Chiodera, P | 1 |
| Coiro, V | 1 |
| Beasley, BL | 1 |
| Davenport, RW | 1 |
| Chase, TN | 1 |
| Fuller, RW | 1 |
| Walsh, SL | 1 |
| Wagner, GC | 1 |
1 trial available for fenfluramine and Parkinson Disease
| Article | Year |
|---|---|
ACTH/cortisol involvement in the serotonergic disorder affecting the parkinsonian brain.
Topics: Adrenocorticotropic Hormone; Aged; Analysis of Variance; Case-Control Studies; Corticotropin-Releasi | 1997 |
5 other studies available for fenfluramine and Parkinson Disease
| Article | Year |
|---|---|
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System S | 2011 |
Prolactin and cortisol responses to fenfluramine in Parkinson's disease.
Topics: Adult; Aged; Brain; Depressive Disorder; Female; Fenfluramine; Humans; Hydrocortisone; Male; Middle | 1996 |
Fenfluramine hydrochloride treatment of parkinsonism.
Topics: Aged; Drug Evaluation; Female; Fenfluramine; Humans; Male; Middle Aged; Parkinson Disease; Serotonin | 1977 |
Fenfluramine and Parkinson's disease.
Topics: Drug Evaluation; Fenfluramine; Humans; Parkinson Disease; Serotonin | 1977 |
Motor impairments after methamphetamine-induced neurotoxicity in the rat.
Topics: Animals; Avoidance Learning; Disease Models, Animal; Dopamine; Fenfluramine; Levodopa; Male; Methamp | 1992 |